Why the study?
Does intravenous infusion of mesenchymal stem cells improve cardiac function and reduce fibrosis in doxorubicin-induced dilated cardiomyopathy in mice?
Does intravenous infusion of mesenchymal stem cells improve cardiac function and reduce fibrosis in doxorubicin-induced dilated cardiomyopathy in mice?
Intravenous infusion of mesenchymal stem cells improves cardiac function in a mouse model of dilated cardiomyopathy, with myocardial homing mediated by the MCP-1/CCR2 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for MSC homing in DCM models; leaves open translation to human therapy.
Guo et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: